These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re: Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Nazm N; Dubey S; Gandhi M; Pegu J Am J Ophthalmol; 2010 Mar; 149(3):525-6; author reply 526-7. PubMed ID: 20172078 [No Abstract] [Full Text] [Related]
4. The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease? Robin AL; Frick KD; Katz J; Budenz D; Tielsch JM Arch Ophthalmol; 2004 Mar; 122(3):376-8. PubMed ID: 15006854 [No Abstract] [Full Text] [Related]
5. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range. Varma R; Hwang LJ; Grunden JW; Bean GW; Sultan MB Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617 [TBL] [Abstract][Full Text] [Related]
7. Evolving global risk assessment of ocular hypertension to glaucoma. Fechtner RD; Khouri AS Curr Opin Ophthalmol; 2007 Mar; 18(2):104-9. PubMed ID: 17301610 [TBL] [Abstract][Full Text] [Related]
8. Uniocular drug trials. Rotchford AP; King AJ Ophthalmology; 2004 Dec; 111(12):2315; author reply 2315-6. PubMed ID: 15582097 [No Abstract] [Full Text] [Related]
9. [When and how we start the treatment in patients with ocular hypertension or in glaucoma suspects?]. Stefan C; Ene L; Coravu CO Oftalmologia; 2014; 58(1):15-7. PubMed ID: 25145118 [TBL] [Abstract][Full Text] [Related]
10. Uniocular drug trial. Jones R; Triana MI; Zaslow K; Sponsel WE Ophthalmology; 2005 Jun; 112(6):1170; author reply 1170-1. PubMed ID: 15936449 [No Abstract] [Full Text] [Related]
11. [Does the ocular hypertension need treatment]. Călugăru M; Călugăru D Oftalmologia; 2006; 50(1):46-56. PubMed ID: 16773938 [TBL] [Abstract][Full Text] [Related]
13. Mean standard deviations for common glaucoma treatments. Stewart WC; Stewart JA; Nelson LA; Kruft B Acta Ophthalmol; 2009 Feb; 87(1):112-4. PubMed ID: 18494738 [No Abstract] [Full Text] [Related]
14. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Bean GW; Camras CB Surv Ophthalmol; 2008 Nov; 53 Suppl1():S69-84. PubMed ID: 19038626 [TBL] [Abstract][Full Text] [Related]
16. The 10-year incidence of glaucoma among patients with treated and untreated ocular hypertension. Gordon MO; Gao F; Beiser JA; Miller JP; Kass MA Arch Ophthalmol; 2011 Dec; 129(12):1630-1. PubMed ID: 22159688 [No Abstract] [Full Text] [Related]
19. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591 [TBL] [Abstract][Full Text] [Related]
20. Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Kass MA; Gordon MO; Kymes SM Arch Ophthalmol; 2005 Jul; 123(7):1021-2. PubMed ID: 16009857 [No Abstract] [Full Text] [Related] [Next] [New Search]